Evidence map›Paper›PMID 38643449›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2024

Kurarinone, a flavonoid from Radix Sophorae Flavescentis, inhibits RANKL-induced osteoclastogenesis in mouse bone marrow-derived monocyte/macrophages.

Ling Long, Hao Luo, Yi Wang, Jiaxiang Gu, Jiachao Xiong, Xiaokai Tang, Hao Lv, Faxin Zhou, Kai Cao, Sijian Lin

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Kurarinone: From chemistry to pharmacological values-A review.Iranian journal of basic medical sciences · 2026
    Review
  2. Article
  3. Review
  4. [Kaempferol in improving chemotherapy-induced myelosuppression: A scoping review].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ling LongJiujiang Hospital of Traditional Chinese Medicine, Jiujiang, 332000, Jiangxi, China.
Hao LuoJiujiang Hospital of Traditional Chinese Medicine, Jiujiang, 332000, Jiangxi, China.
Yi WangJiujiang Hospital of Traditional Chinese Medicine, Jiujiang, 332000, Jiangxi, China.
Jiaxiang GuOrthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330209, Jiangxi, China.
Jiachao XiongOrthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330209, Jiangxi, China.
Xiaokai TangOrthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330209, Jiangxi, China.
Hao LvOrthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330209, Jiangxi, China.
Faxin ZhouOrthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330209, Jiangxi, China.
Kai CaoOrthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330209, Jiangxi, China. caokai@ncu.edu.cn.
Sijian LinRehabilitation Medicine Department, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China. doreenlin330@163.com.
Nanchang University · CNSecond Affiliated Hospital of Nanchang University · CN

Funding

Clinical Cultivation Project of The First Affiliated Hospital of Nanchang University No. YFYLCYJPY202202Double-thousand Plan Program of Jiangxi Province jxsq2023201023Key Project of Natural Science Foundation of Jiangxi Province 20202ACB206004Major Discipline Academic and Technical Leaders Training Program of Jiangxi Province 20204BCJ22026National Natural Science Foundation of China 81460405Research Project of Health Commission of Jiangxi Province (No.202310504); Cultivation Project of Science and Technology Department of Jiangxi Province 20212BAG70004Research Project of Jiangxi Provincial Department of Education GJJ2200182
6 · The paper itself

Abstract

Inflammation-induced osteoclast proliferation is a crucial contributor to impaired bone metabolism. Kurarinone (KR), a flavonoid extracted from the Radix Sophorae Flavescentis, exhibits notable anti-inflammatory properties. Nevertheless, the precise influence of KR on osteoclast formation remains unclear. This study's objective was to assess the impact of KR on osteoclast activity in vitro and unravel its underlying mechanism. Initially, a target network for KR-osteoclastogenesis-osteoporosis was constructed using network pharmacology. Subsequently, the intersecting targets were identified through the Venny platform and a PPI network was created using Cytoscape 3.9.1. Key targets within the network were identified employing topological algorithms. GO enrichment and KEGG pathway analysis were then performed on these targets to explore their specific functions and pathways. Additionally, molecular docking of potential core targets of KR was conducted, and the results were validated through cell experiments. A total of 83 target genes overlapped between KR and osteoclastogenesis-osteoporosis targets. Enrichment analysis revealed their role in inflammatory response, protein tyrosine kinase activity, osteoclast differentiation, and MAPK and NF-κB signaling pathways. PPI analysis and molecular docking demonstrate that key targets MAPK14 and MAPK8 exhibit more stable binding with KR compared to other proteins. In vitro experiments demonstrate that KR effectively inhibits osteoclast differentiation and bone resorption without cellular toxicity. It suppresses key osteoclast genes (NFATc1, c-Fos, TRAP, MMP9, Ctsk, Atp6v2), hinders IκB-α degradation, and inhibits ERK and JNK phosphorylation, while not affecting p38 phosphorylation. The results indicate that KR may inhibit osteoclast maturation and bone resorption by blocking NF-κB and MAPK signaling pathways, suggesting its potential as a natural therapeutic agent for osteoporosis.

Indexed as

FlavonoidsMacrophagesMolecular Docking SimulationOsteoclastsOsteogenesisRANK LigandAnimalsCell DifferentiationMiceMice, Inbred C57BLMonocytesNF-kappa BSignal TransductionSophoraFlavonoidskurarinoneNF-kappa BRANK LigandTnfsf11 protein, mouseKurarinoneMolecular dockingNetwork pharmacologyOsteoclast differentiationOsteoporosis

Identifiers

PMID38643449
OpenAlexW4394989197

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.